Addleshaw Goddard and Hogan Lovells are among the firms to have advised on the £135m Aim listing of pharmaceutical company Clinigen, a rare UK IPO for the industry.
Clinigen, which supplies drugs for clinical tests, has raised £50m from the listing, including a £10 million cash injection which the group is expected to spend on new acquisitions. The company said it would have a market capitalisation of £135m.
Addleshaws acted for the company, which hired Numis Securities to conduct the float. The Addleshaws team was led by Manchester corporate partner Richard Lee, with US firm Fox Rothschild understood to have provided US input.
Numis, the sole bookrunner on the IPO, turned to Hogan Lovells for advice, led by London corporate partner Guy Potel, who advised alongside Numis general counsel Michael Lee. US securities partner Peter Kohl provided US advice.
Background to this deal:
Hogan Lovells private equity co-head Alan Greenough had an existing relationship with Numis before the firm won this role, with Greenough acting alongside them to advise AIM listed Abcam on its acquisition of Epitomics International for US $170m in March this year.
For the best of The Lawyer’s transactional coverage every Monday, sign up to our new weekly Deals Insider email here